China Resources Pharma’s $2 billion IPO, which will be the largest-ever Hong Kong pharma IPO, will price on October 20; Samsung Biologics is planning a $2 billion Korean IPO and WuXi Biologics expects to raise $500 million in a Hong Kong initial offering next year; 3SBio paid $100 million to market two AstraZeneca diabetes products in China; TransThera Biosciences, a Nanjing startup, raised $10 million in an A Round led by Hong Kong’s Morningside; EpimAb Biotherapeutics of Shanghai formed a cross-licensing partnership with the UK’s Kymab for bispecific immuno-oncology antibodies; ASLAN Pharma of Singapore will collaborate with Singapore’s Nanyang Technological University to develop mAb fragments; the Jackson Laboratory of the US is planning a large genomics collaboration in Wenzhou, Zhejiang province; and GlaxoSmithKline has formed four partnerships with China scientists to build its neurological R&D program.
